DBV Technologies And 2 Other Stocks Under $2 Insiders Are Buying

DBV Technologies和其他两只低于2美元的股票内部人士正在买入

Benzinga · 02/09 06:02

The Dow Jones index closed higher by around 50 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

Dalrada Financial

The Trade: Dalrada Financial Corporation (OTC:DFCO) Chief Executive Officer Brian Bonar acquired a total of 52,600 shares an average price of $0.22. To acquire these shares, it cost around $11,831.
What's Happening: The company's stock fell around 16% over the past month.
What Dalrada Financial Does: Dalrada Financial Corp is a United States-based company engaged in providing financial, insurance, benefit, and business process outsourcing products and services to companies.

Research Frontiers

The Trade: Research Frontiers Incorporated (NASDAQ:REFR) Director Darryl Daigle acquired a total of 1,000 shares at at an average price of $1.00. To acquire these shares, it cost around $1,000.
What's Happening: On Nov. 2, Research Frontiers posted a narrower third-quarter loss.
What Research Frontiers Does: Research Frontiers Inc is engaged in the development and marketing of technology and devices to control the flow of light.

DBV Technologies

The Trade: DBV Technologies S.A. (NASDAQ:DBVT) Director Adora Ndu acquired a total of 1,825 shares at an average price of $0.89. The insider spent around $1,624 to buy those shares.
What's Happening: On Nov. 10, DBV Technologies announced 2-year results from ongoing Phase 3 open-label extension to the EPITOPE trial (EPOPEX) of Viaskin peanut in toddlers.
What DBV Technologies Does: DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin.

Don't forget to check out our premarket coverage here

The Dow Jones index closed higher by around 50 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

道琼斯指数周四收高约50点。当内部人士购买或出售股票时，这表明他们对公司前景的信心或担忧。对细价股感兴趣的投资者和交易者可以将此视为他们整体投资或交易决策的一个因素。

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

以下是近期一些值得注意的细价股内幕交易。欲了解更多，请查看 本辛加的内幕交易 平台。

Dalrada Financial

达尔拉达金融

The Trade: Dalrada Financial Corporation (OTC:DFCO) Chief Executive Officer Brian Bonar acquired a total of 52,600 shares an average price of $0.22. To acquire these shares, it cost around $11,831.
What's Happening: The company's stock fell around 16% over the past month.
What Dalrada Financial Does: Dalrada Financial Corp is a United States-based company engaged in providing financial, insurance, benefit, and business process outsourcing products and services to companies.

交易：达尔拉达金融公司（场外交易代码：DFCO）首席执行官布莱恩·博纳尔 共收购了52,600股股票 平均价格为0.22美元。收购这些股票的成本约为11,831美元。
发生了什么：该公司的股票在过去一个月中下跌了约16％。
Dalrada Financial做什么：Dalrada Financial Corp是一家总部位于美国的公司，致力于为公司提供财务、保险、福利和业务流程外包产品和服务。

Research Frontiers

研究前沿

The Trade: Research Frontiers Incorporated (NASDAQ:REFR) Director Darryl Daigle acquired a total of 1,000 shares at at an average price of $1.00. To acquire these shares, it cost around $1,000.
What's Happening: On Nov. 2, Research Frontiers posted a narrower third-quarter loss.
What Research Frontiers Does: Research Frontiers Inc is engaged in the development and marketing of technology and devices to control the flow of light.

贸易：研究前沿公司（纳斯达克股票代码：REFR）董事达里尔·戴格尔 共收购了1,000股股票 平均价格为1.00美元。收购这些股票的成本约为1,000美元。
发生了什么：11月2日，Research Frontiers公布的第三季度亏损幅度较小。
Research Frontiers做什么：Research Frontiers Inc从事控制光流的技术和设备的开发和营销。

DBV Technologies

DBV 科技

The Trade: DBV Technologies S.A. (NASDAQ:DBVT) Director Adora Ndu acquired a total of 1,825 shares at an average price of $0.89. The insider spent around $1,624 to buy those shares.
What's Happening: On Nov. 10, DBV Technologies announced 2-year results from ongoing Phase 3 open-label extension to the EPITOPE trial (EPOPEX) of Viaskin peanut in toddlers.
What DBV Technologies Does: DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin.

交易：DBV Technologies S.A.（纳斯达克股票代码：DBVT）董事阿多拉·恩杜 共收购了1,825股股票 平均价格为0.89美元。知情人士花费了约1,624美元购买了这些股票。
发生了什么：11月10日，DBV Technologies公布了正在进行的针对幼儿的Viaskin花生的EPITOPE试验（EPOPEX）的第三阶段开放标签延期的两年结果。
DBV Technologies的所作所为：DBV Technologies SA是一家临床阶段的专业生物制药公司，专注于通过开发名为Viaskin的新型技术平台来改变免疫疗法领域。

Don't forget to check out our premarket coverage here

别忘了在这里查看我们的上市前报道

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。更多信息